Cargando…
De-escalation of biological therapy in inflammatory bowel disease patients following prior dose escalation
BACKGROUND: Limited data are available on biological therapy de-escalation after prior escalation in inflammatory bowel disease (IBD) patients. This study aimed to assess the frequency and success rate of de-escalation of biological therapy in IBD patients after prior dose escalation and to evaluate...
Autores principales: | Thomas, Pepijn W. A., Smits, Lisa J. T., Te Groen, Maarten, West, Rachel L., Russel, Maurice G. V. M., Jansen, Jeroen M., Römkens, Tessa E. H., Hoentjen, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams And Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983943/ https://www.ncbi.nlm.nih.gov/pubmed/34974465 http://dx.doi.org/10.1097/MEG.0000000000002336 |
Ejemplares similares
-
Long-term effectiveness and safety of ustekinumab in Crohn’s disease: a prospective cohort study
por: Thomas, Pepijn W.A., et al.
Publicado: (2022) -
Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis
por: Savelkoul, Edo H J, et al.
Publicado: (2022) -
Discrepancy between patient‐ and healthcare provider‐reported adverse drug reactions in inflammatory bowel disease patients on biological therapy
por: Thomas, Pepijn W. A., et al.
Publicado: (2021) -
Impact of Biological Therapies and Tofacitinib on Real-world Work Impairment in Inflammatory Bowel Disease Patients: A Prospective Study
por: Thomas, Pepijn W A, et al.
Publicado: (2022) -
Inflammatory bowel disease patients provide reliable self‐reported medical information: A multicentre prospective pharmacovigilance monitoring system
por: Thomas, Pepijn W. A., et al.
Publicado: (2020)